Education Session

EDUCATION SESSION

08:00 – 09:30, Hall 1 and 14:15 – 15:45, Hall 2

MULTIPLE MYELOMA

Chair: H Einsele (University Würzburg, Würzburg, Germany)

• PATHOGENESIS OF MULTIPLE MYELOMA

  G Morgan (Institute of Cancer Research & the Royal Marsden NHS Foundation Trust, London, United Kingdom)

• EXPERIMENTAL AGENTS KNOCKING AT THE DOOR OF MYELOMA
  TREATMENT

  N Munshi (Dana Farber Cancer Institute, Boston, USA)

• TREATMENT OPTIONS FOR MYELOMA IN 2009
  J Bladé (Hospital Clinic, Barcelona, Spain)

EDUCATION SESSION

08:00 – 09:30, Hall 2 and 14:15 – 15:45, Hall 1

ACUTE MYELOID LEUKEMIA

Chair: M Theobald (University Medical Center Utrecht, Utrecht, The Netherlands)

• ACUTE MYELOID LEUKEMIA BIOLOGY & LEUKEMIC STEM CELLS

  B Huntly (University of Cambridge, Cambridge, United Kingdom)

• MINIMAL RESIDUAL DISEASE

  G Saglio (University of Turin, Turin, Italy)

• RISK ADAPTED TREATMENT OF ACUTE MYELOID LEUKEMIA

  J Sierra (Hospital Santa Creu i Sant Pau, Barcelona Spain)

EDUCATION SESSION

08:00 – 09:30, Hall 3 and 14:15 – 15:45, Hall 3

DIFFUSE LARGE B-LYMPHOMA

Chair: G Gaidano (University Studi Piemonte Orientale, Novara, Italy)

• MOLECULAR BASIS OF AGGRESSIVE LYMPHOMA

  A Rosenwald (University of Würzburg, Würzburg, Germany)

• DEVELOPING NEW TREATMENTS FOR DIFFUSE LARGE B-CELL LYMPHOMA

  M Shipp (Harvard Medical School, Boston, USA)

• TREATMENT OPTIONS FOR RELAPSING PATIENTS

  C Gisselbrecht (Hôpital Saint Louis, Paris, France)

EDUCATION SESSION

08:00 – 09:30, Hall 15.2 and 14:15 – 15:45, Hall 2.1 (stage)

HODGKIN DISEASE

Chair: M André (Grand Hôpital de Charleroi, Charleroi, Belgium)

• LYMPHOCYTE-PREDOMINANT HODGKIN'S LYMPHOMA IN CHILDREN
  AND YOUNG ADULTS

  J Landman-Parker (Hôpital Trousseau APHP, Paris, France)

• THE ROLE OF PET IN THE MANAGEMENT OF HODGKIN'S LYMPHOMA

  A Gallamini (Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy)

• RECENT ADVANCES IN THE TREATMENT OF EARLY STAGES OF HODGKIN’S LYMPHOMA

  A Engert (Klinikum der Universität zu Köln, Cologne, Germany)

EDUCATION SESSION

08:00 – 09:30, Hall 2.1 (stage) and 14:15 – 15:45, Hall 7

CHRONIC MYELOID LEUKEMIA

Chair: M Baccarani (University of Bologna, Bologna, Italy)

• STEM CELL PERSISTENCE IN CHRONIC MYELOID LEUKEMIA

  M Deininger (Oregon Health & Science University, Portland, USA)

• DYNAMICS OF MUTATED CLONES

  A Hochhaus (Universitätsmedizin Mannheim, Mannheim, Germany)

• SECOND GENERATION TKI’S: WHICH AND WHEN

  H Kantarjian (MD Anderson Cancer Center, Houston, USA)

EDUCATION SESSION

08.00 – 09.30, Hall 7 and 14:15 – 15:45, Hall 14.2

BLEEDING DISORDERS

Chair: B Lämmle (Inselspital - University Hospital, Bern, Switzerland)

• VON WILLEBRAND FACTOR ROLE IN HEMOSTASIS

  K Vanhoorelbeke (IRC - KU Leuven Campus Kortrijk, Kortrijk, Belgium)

• PHENOTYPE, GENOTYPE AND CLASSIFICATION IN VON WILLEBRAND DISEASE

  A Goodeve (University of Sheffield, Sheffield, United Kingdom)

• TREATMENT OPTIONS IN VON WILLEBRAND DISEASE

  A Federici (Angelo Bianchi Bonomi Hemophilia Thrombosis Center, Milan, Italy)

EDUCATION SESSION

08:00 – 09:30 hrs, Hall 14.2 and 14:15 – 15:45, Hall 4/5

UNCOMMON LYMPHOPROLIFERATIVE DISORDERS

Chair: T Lamy (CHU de Rennes, Rennes, France)

• NK CELL DISORDERS

  G Semenzato (Padova University School of Medicine, Padova, Italy)

• MOLECULAR BASIS AND CLASSIFICATION OF LGL DISORDERS

  Estella Matutes (Royal Marsden Hospital / Institute of Cancer Research, London, United Kingdom)

• THERAPEUTIC STRATEGIES IN HAIRY CELL LEUKEMIA

  D Catovsky (Institute of Cancer Research, Sutton, United Kingdom)

EDUCATION SESSION

08:00 – 09:30, Hall 4/5 and 14:15 – 15:45, Hall 6

PEDIATRIC HEMATOLOGICAL MALIGNANCIES

Chair: A Biondi (Centro M.Tettamanti- Clinica Pediatrica Università Milano-Bicocca, Monza, Italy

• PEDIATRIC MYELODYSPLASTIC SYNDROME

  C Niemeyer (Klinik IV: Pädiatrische Hämatologie und Onkologie, Freiburg, Germany)

• PEDIATRIC ACUTE MYELOID LEUKEMIA

  G Kaspers (VU University Medical Center Amsterdam, Amsterdam,
  The Netherlands)

• PEDIATRIC MYELOPROLIFERATIVE DISORDERS

  M Randi (University of Padova, Padova, Italy)

EDUCATION SESSION

08:00 – 09:30, Hall 6 and 14:15 – 15:45, Hall 9

RED CELL DISEASE

Chair: S Thein (King's College London School of Medicine, London, United Kingdom)

• RED CELL MEMBRANE DISORDERS

  N Mohandas, (New York Blood Center, New York, USA)

• PREDICTORS OF CLINICAL SEVERITY IN SICKLE CELL DISEASE

  M Steinberg (Boston University School of Medicine, Boston, USA)

• DIAGNOSIS, TREATMENT AND MANAGEMENT OF ERYTHROCYTOSIS

  M McMullin (Queen’s University, Belfast, Northern Ireland)

EDUCATION SESSION

09:45 – 11:15, Hall 1 and 16:00 – 17:30, Hall 2

MYELOPROLIFERATIVE DISORDERS

Chair: H Pahl (University Hospital Freiburg, Freiburg, Germany)

• MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS

  R Kralovics (Center for Molecular Medicine, Austrian Academy of Sciences,
  Vienna, Austria)

• RISK STRATIFICATION BASED APPROACH TO THE TREATMENT OF PRIMARY MYELOFIBROSIS

  R Hoffman (Mount Sinai School of Medicine, New York, USA)

• INTERFERON IN THE TREATMENT OF MYELOPROLIFERATIVE
  DISORDERS

  J Kiladjian (Hôpital Avicenne, Bobigny, France)

EDUCATION SESSION

09:45 – 11:15, Hall 2 and 16:00 – 17:30, Hall 1

CHRONIC LYMPHOCYTIC LEUKEMIA

Chair: F Caligaris-Cappio (University Scientific Institute San Raffaele, Milan, Italy)

• THE ORIGIN OF CHRONIC LYMPHOCYTIC LEUKEMIA

  U Klein (Columbia University, New York, USA)

• CLINICAL IMPLICATIONS OF BIOLOGICAL MARKERS IN CHRONIC
  LYMPHOCYTIC LEUKEMIA

  R Rosenquist (Uppsala University, Uppsala, Sweden)

• RISK ADAPTED CHRONIC LYMPHOCYTIC LEUKEMIA MANAGEMENT

  P Hillmen (St. James’s Institute of Oncology, Leeds, United Kingdom)

EDUCATION SESSION

09:45 – 11:15, Hall 3 and 16:00 – 17:30, Hall 3

ACUTE LYMPHOBLASTIC LEUKEMIA

Chair: R Pieters (Erasmus Medical Center- Sophia Children’s Hospital, Rotterdam, The Netherlands)

• GENETIC PROFILING IN B ACUTE LYMPHOBLASTIC LEUKEMIA

  C Mullighan (St. Jude Children's Research Hospital, Memphis, USA)

• GENETIC AND EPIGENETIC PROGRAMS IN MLL-REARRANGED
  ACUTE LYMPHOBLASTIC LEUKEMIA

  S Armstrong (Children’s Hospital Boston, Boston, USA)

• DOWN AND B ACUTE LYMPHOBLASTIC LEUKEMIA

  S Izraeli (Sheba Medical Center, Ramat Gan, Israel)

EDUCATION SESSION

09:45 – 11:15, Hall 15.2 and 16:00 – 17:30, Hall 2.1 (stage)

MYELODYSPLASTIC SYNDROMES

Chair: W Hofmann (Charité – University Hospital, Mannheim, Germany)

• PATHOGENESIS AND BASIC ASPECTS OF MYELODYSPLASTIC
  SYNDROME

  A Raza (St. Vincent's Comprehensive Cancer Center, New York, USA)

• MYELODYSPLASTIC SYNDROME: BENCH TO BEDSIDE AND BACK

  S Nimer (Memorial Sloan-Kettering Cancer Center, New York, USA)

• TREATMENT OF MYELODYSPLASTIC SYNDROME

  M Cazzola (University of Pavia, Pavia, Italy)

EDUCATION SESSION

09:45 – 11:15, Hall 2.1 (stage) and 16:00 – 17:30, Hall 7

STEM CELL TRANSPLANTATION

Chair: J Cornelissen (Erasmus Medical Center, Rotterdam, The Netherlands)

• IMMUNOBIOLOGY OF REDUCED INTENSITY CONDITIONING IN STEM CELL TRANSPLANTATION

  B Sandmaier (Fred Hutchinson Cancer Research Center, Seattle, USA)

• REDUCED INTENSITY CONDITIONING AS A PLATFORM FOR IMMUNOTHERAPY

  J Barrett (National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, USA)

• CURRENT STATUS OF TREATMENT WITH ALLOGENEIC STEM CELL TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING

  A Gratwohl (University Hospital Basel, Basel, Switzerland)

EDUCATION SESSION

09:45 – 11:15, Hall 7 and 16:00 – 17:30, Hall 14.2

THROMBOSIS

Chair: I Peake (University of Sheffield, Sheffield, United Kingdom)

• GENETICS OF THROMBOSIS

  P Reitsma (Leiden University Medical Center, Leiden, The Netherlands)

• BENCH TO BEDSIDE IN THROMBOSIS

  T Baglin (Addenbrooke’s NHS Trust, Cambridge, United Kingdom)

• THROMBIN OR FACTOR XA: DOES THE TARGET MATTER?

  H Büller (Amsterdam Medical Center, Amsterdam, The Netherlands)

EDUCATION SESSION

09:45 – 11:15, Hall 14.2 and 16:00 – 17:30, Hall 4/5

HEMATOPOIESIS

Chair: T Enver (Weatherall Institute of Molecular Medicine, Oxford, United Kingdom)

• ANATOMY OF THE STEM CELL NICHE

  E Dzierzak (Erasmus Medical Center, Rotterdam, The Netherlands)

• DYNAMICS OF HEMATOPOIETIC STEM CELL COMPARTMENTS

  M Manz (Institute for Research in Biomedicine, Bellinzona, Switzerland)

• TRAFFICKING OF HEMATOPOIETIC STEM CELLS

  T Lapidot (Weizmann Institute of Science, Rehovot, Israël)

EDUCATION SESSION

09:45 – 11:15, Hall 4/5 and 16:00 – 17:30, Hall 6

CLINICAL TRIAL DESIGN

Chair: B Löwenberg (Erasmus Medical Center, Rotterdam, The Netherlands)

• DESIGNING AND INTERPRETING QUALITY OF LIFE AND OTHER
  PATIENT-REPORTED OUTCOMES IN CLINICAL TRIALS

  F Efficace (Italian Group for Adult Hematologic Diseases, Rome, Italy)

• THE USE OF GENOMICS IN TODAY'S CLINICAL TRIAL DESIGN: PITFALLS IN THE STATISTICAL EVALUATION

  R Simon (National Cancer Institute, Bethesda, USA)

• DO COMMONLY USED CLINICAL TRIAL DESIGNS REFLECT CLINICAL REALITY?

  E Estey (University of Washington / Fred Hutchinson Cancer Research Center, Seattle, USA)

EDUCATION SESSION

09:45 – 11:15, Hall 6 and 16:00 – 17:30, Hall 9

TRANSFUSION

Chair: N Avent (University of West England Bristol, United Kingdom)

• TRANSFUSION POLICIES AND CASE STUDIES IN ALLOIMMUNISED SICKLE CELL PATIENTS

  J Moulds (LifeShare Blood Centers, Los Angeles, USA)

• TRANSFUSION PROBLEMS IN STEM CELL TRANSPLANTATION

  D Pamphilon (National Blood Service, Bristol, United Kingdom)

• TRANSFUSION IN NEONATES AND CHILDREN

  N Luban (Children's Hospital, Washington, USA)